Pharma

  • Pfizer HQ entrance
    Image attribution tooltip
    Permission granted by Pfizer
    Image attribution tooltip

    Pfizer expands multibillion-dollar cost-cutting plan

    Hatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer another $1.5 billion by streamlining drug production.

    By • Aug. 4, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    J&J pharma leader to retire; Krystal slumps on gene therapy miss

    Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.

    By BioPharma Dive staff • Aug. 4, 2026
  • A stylized illustration of a pill breaking apart into smaller pills. Explore the Trendline➔
    Image attribution tooltip
    Brian Tucker / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Trendline

    Top 5 stories from BioPharma Dive

    Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

    By BioPharma Dive staff
  • An AstraZeneca logo stands atop an office building in Shanghai, China.
    Image attribution tooltip
    Robert Way via Getty Images
    Image attribution tooltip

    An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.

    In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the pharmaceutical giants.

    By • Aug. 3, 2026
  • An anatomical model of the heart sits on a desk in a doctor's office
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novo setback casts doubt on a new way to treat heart disease

    Ziltivekimab's failure in a key trial spurred share sell-offs for Novo and other biotechs, as it suggested trouble for different cardiovascular drugs that also target inflammation.

    By • July 31, 2026
  • Wall Street buildings
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push

    Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.

    By BioPharma Dive staff • July 29, 2026
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK prepares for patent cliff with $2.5B cost-cutting plan

    The pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss of patents important to its HIV drug franchise.

    By • July 28, 2026
  • Promotional graphic for Season 2 of The Progress Profile: Alzheimer’s Research in Focus, featuring the Pearson and BioPharma Dive logos on a dark blue background with abstract glowing blue wave patterns on the right.
    Image attribution tooltip
    William Walker/BioPharma Dive
    Image attribution tooltip
    Sponsored by Pearson

    [Podcast] (Season 2) The Progress Profile: Alzheimer’s Research in Focus

    This podcast explores how leading Alzheimer’s experts are working to bridge the gap between clinical trial design and frontline care.

    By BioPharma Dive's studioID • July 27, 2026
  • Podcast promo image with a vintage microphone, featuring Almac and BioPharma Dive logos and the title “From Protocol to Patient: Inside Clinical Supply.”
    Image attribution tooltip
    Almac Clinical Services/BioPharma Dive
    Image attribution tooltip
    Sponsored by Almac Clinical Services

    [Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services

    This podcast explores how clinical trial supplies move from early planning to global delivery, ensuring investigational medicines reach patients safely and on time.

    By BioPharma Dive's studioID • Updated May 26, 2026
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi halts development of troubled immune drug in eczema

    The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster. One analyst expects Sanofi to now pursue “strategic action” to boost its pipeline.

    By • July 24, 2026
  • A photo of a building showing a GSK sign in London.
    Image attribution tooltip
    Courtesy of GSK
    Image attribution tooltip

    GSK lung cancer drug gets speedy approval following $10.6B deal

    The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.

    By • July 22, 2026
  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs

    The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is “truthful.”

    By • July 21, 2026
  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis climbs on upbeat drug sales as key readouts loom

    A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.

    By Kristin Jensen • July 21, 2026
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK shelves cough drug acquired in $2B deal

    Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.

    By • July 17, 2026
  • A wall showing a Merck & Co. logo in Kenilworth, New Jersey
    Image attribution tooltip
    Courtesy of Merck & Co.
    Image attribution tooltip

    Merck wins first approval of a PCSK9 cholesterol pill

    The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.  

    By • Updated July 16, 2026
  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Celcuity gains FDA approval for closely watched breast cancer drug

    Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.

    By • Updated July 15, 2026
  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip

    Roche scraps two Ionis-partnered Huntington’s drugs

    The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.

    By • July 9, 2026
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK ends brain drug alliance with Alector

    Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.

    By • July 9, 2026
  • An AstraZeneca logo stands atop an office building in Shanghai, China.
    Image attribution tooltip
    Robert Way via Getty Images
    Image attribution tooltip
    China competition

    AstraZeneca, GSK intensify China ties with Sino Biopharm deals

    The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions in the U.S.

    By • July 8, 2026
  • A Novartis logo is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip

    Novartis to acquire ADC developer in a deal worth up to $1.5B

    The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.

    By • July 6, 2026
  • Exterior view of the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group F. Hoffmann-La Roche
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roche KRAS drug succeeds in head-to-head lung cancer study

    The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.

    By Kristin Jensen • July 2, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program

    The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.

    By BioPharma Dive staff • June 30, 2026
  • A bottle of pills lays on top of a sheet of $100 bills.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Theravance, after clinical setbacks, agrees to $929M buyout

    The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.

    By • June 29, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services

    Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.

    By BioPharma Dive staff • June 26, 2026
  • Pill gavel
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    On second try, Acadia drug gets nod from European regulators

    The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.

    By • June 26, 2026
  • Pfizer's logo cast in metal.
    Image attribution tooltip
    Jeenah Moon via Getty Images
    Image attribution tooltip

    Pfizer drug acquired in Seagen deal disappoints in lung cancer study

    The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.

    By • June 23, 2026